RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new combination of drugs (PolaR-ICE) for people with diffuse large B-cell lymphoma that has come back or hasn't responded to initial treatment. The goal is to see if adding a targeted drug (polatuzumab vedotin) to standard chemotherapy can improve the chance of…
Matched conditions: RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…
Matched conditions: RECURRENT TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:42 UTC